Klinikinės baigtys

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (atsiveria naujas langas)

Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A

Šaltinis‎: Lancet Haematol 2018;5(3):e117-e126.

Kodas‎: PubMed 29396092

DOI‎: 10.1016/S2352-3026(18)30016-4

https://www.ncbi.nlm.nih.gov/pubmed/29396092 (atsiveria naujas langas)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (atsiveria naujas langas)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Šaltinis‎: Cancer 2013;119(1):107-14.

Kodas‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (atsiveria naujas langas)

HEMATOLOGIJA

Klinikinės baigtys

lietuvių

Klinikinės baigtys

https://assetsnffrgf-a.akamaihd.net/assets/ct/1add6d1d93/images/syn_placeholder_sqr.png

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (atsiveria naujas langas)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (atsiveria naujas langas)

Susisiekite su vietiniu atstovu

Medicininės informacijos paketai

Filmai

Klinikinės baigtys

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (atsiveria naujas langas)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (atsiveria naujas langas)

Susisiekite su vietiniu atstovu

Medicininės informacijos paketai

Filmai

Kalbos pasirinkimas

Dalintis